Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update

by @JTC_PALIdev | Mar 23, 2023 | Press Releases

Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 — Palisade Bio, Inc. (Nasdaq: PALI)...

Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent

by @JTC_PALIdev | Mar 1, 2023 | Press Releases

Carlsbad, CA, March 01, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office...

Palisade Bio Promotes Robert McRae to Chief Operating Officer

by @JTC_PALIdev | Feb 8, 2023 | Press Releases

Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA, Feb. 08, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical...

Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million

by @JTC_PALIdev | Jan 10, 2023 | Press Releases

Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI)...

Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event

by @JTC_PALIdev | Jan 9, 2023 | Press Releases

Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 — Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that...

Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules

by @JTC_PALIdev | Jan 4, 2023 | Press Releases

Carlsbad, CA, Jan. 04, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered...